Evaluating markers for treatment selection based on survival time
- PMID: 21611957
- DOI: 10.1002/sim.4258
Evaluating markers for treatment selection based on survival time
Abstract
For many medical conditions, several treatment options may be available for treating patients. We consider evaluating markers based on a simple treatment selection policy that incorporates information on the patient's marker value. For example, colon cancer patients may be treated by surgery alone or surgery plus chemotherapy. The c-myc gene expression level may be used as a biomarker for treatment selection. Although traditional regression methods may assess the effect of the marker and treatment on outcomes, it is more appealing to quantify directly the potential impact on the population of using the marker to select treatment. A useful tool is the selection impact (SI) curve proposed by Song and Pepe for binary outcomes (Biometrics 2004; 60:874-883). However, the current SI method does not deal with continuous outcomes, nor does it allow to adjust for other covariates that are important for treatment selection. In this paper, we extend the SI curve for general outcomes, with a specific focus on survival time. We further propose the covariate-specific SI curve to incorporate covariate information in treatment selection. Nonparametric and semiparametric estimators are developed accordingly. We show that the proposed estimators are consistent and asymptotically normal. The performance is assessed by simulation studies and illustrated through an application to data from a cancer clinical trial.
Copyright © 2011 John Wiley & Sons, Ltd.
Similar articles
-
Evaluating markers for selecting a patient's treatment.Biometrics. 2004 Dec;60(4):874-83. doi: 10.1111/j.0006-341X.2004.00242.x. Biometrics. 2004. PMID: 15606407
-
Semiparametric estimation of time-dependent ROC curves for longitudinal marker data.Biostatistics. 2004 Oct;5(4):615-32. doi: 10.1093/biostatistics/kxh013. Biostatistics. 2004. PMID: 15475423
-
Covariate-adjusted non-parametric survival curve estimation.Stat Med. 2011 May 20;30(11):1243-53. doi: 10.1002/sim.4216. Epub 2011 Feb 23. Stat Med. 2011. PMID: 21344475
-
Semiparametric approaches for joint modeling of longitudinal and survival data with time-varying coefficients.Biometrics. 2008 Jun;64(2):557-66. doi: 10.1111/j.1541-0420.2007.00890.x. Epub 2007 Aug 28. Biometrics. 2008. PMID: 17725812
-
Implications of prognostic markers in brain tumors.Clin Lab Med. 1999 Dec;19(4):833-47. Clin Lab Med. 1999. PMID: 10572718 Review.
Cited by
-
Evaluating biomarkers for treatment selection from reproducibility studies.Biostatistics. 2022 Jan 13;23(1):173-188. doi: 10.1093/biostatistics/kxaa018. Biostatistics. 2022. PMID: 32424421 Free PMC article. Clinical Trial.
-
Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data.BMC Med. 2019 Jun 18;17(1):113. doi: 10.1186/s12916-019-1345-2. BMC Med. 2019. PMID: 31208412 Free PMC article.
-
Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer.Contemp Clin Trials. 2017 Dec;63:30-39. doi: 10.1016/j.cct.2017.08.004. Epub 2017 Aug 14. Contemp Clin Trials. 2017. PMID: 28818434 Free PMC article. Clinical Trial.
-
Estimation of treatment policies based on functional predictors.Stat Sin. 2014 Jul;24(3):1461-1485. doi: 10.5705/ss.2012.196. Stat Sin. 2014. PMID: 25165416 Free PMC article.
-
EFFECTIVELY SELECTING A TARGET POPULATION FOR A FUTURE COMPARATIVE STUDY.J Am Stat Assoc. 2013 Jan 1;108(502):527-539. doi: 10.1080/01621459.2013.770705. J Am Stat Assoc. 2013. PMID: 24058223 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
